Grapefruit News and Research

RSS

Complementary, alternative therapies for heart failure have some benefits and potential risks

There are some benefits and potentially serious risks when people with heart failure use complementary and alternative medicines (CAM), to manage symptoms, so involving the health care team is important for safety, according to a new American Heart Association scientific statement published today in the Association's flagship, peer-reviewed journal Circulation.

8 Dec 2022

TTUHSC secures $1.87 million grant to investigate the impact of vitamin A depletion on Alzheimer’s disease

Ongoing research suggests that an accumulation of toxic reactive oxygen species (ROS) in the area of the brain known as the hippocampal dentate gyrus may begin early on in patients with Alzheimer's disease.

21 Mar 2022

Foods high in flavonoids may lower risk of cognitive decline

A new study shows that people who eat a diet that includes at least half a serving per day of foods high in flavonoids like strawberries, oranges, peppers and apples may have a 20% lower risk of cognitive decline.

28 Jul 2021

Mustard seed, wall rocket and turmeric extracts show potential against SARS-CoV-2 in vitro

Researchers in Spain have identified plant extracts that may be of interest in the search for treatments of coronavirus disease 2019 (COVID-19) and serve as a basis for future chemical, in vivo, and clinical trials.

1 Jul 2021

Xylitol and grapefruit seed extract shows promise in preventing SARS-CoV-2 infection, study finds

A team of researchers at the Feinberg School of Medicine demonstrated that xylitol and grapefruit seed extract (GSE) could prevent SARS-CoV-2 infection. These can be used as a nasal spray to contain the spread of the coronavirus.

7 Dec 2020

Xylitol and grapefruit seed extract nasal spray could help COVID-19 patients

United States based researchers have published a report exploring the potential role of Xylitol and Grapefruit seed extract (in the form of a nasal spray) in treating COVID-19.

16 Nov 2020

Natural compund in cedar and grapefruit skin could help repel mosquitoes and ticks says CDC

Over the last few years, there has been a rise in the number of cases of diseases caused by mosquito and tick bites. The U.S. Centers for Disease Control and Prevention (CDC) has said that a natural chemical compound could help combat this problem. This compound Nootkatone is found commonly in cedar trees, and grapefruit skin says the organization.

11 Aug 2020

Using supercomputers to screen drugs for deadly heart arrhythmias

Death from sudden cardiac arrest makes headlines when it strikes athletes. But it also causes the most deaths by natural causes in the U.S. estimated at 325,000 per year.

14 May 2020

Aromatherapy may alleviate nurses’ on-the-job stress, study suggests

Even under normal circumstances, nursing can be a stressful profession. The COVID-19 pandemic only exacerbates it.

3 May 2020

Sugary drinks have a negative impact on blood cholesterol, which increases heart disease risk

Drinking 12 ounces of sugary drinks more than once per day is linked to lower levels of high-density lipoprotein cholesterol (HDL-C), ("good" cholesterol), and higher levels of triglycerides, in middle-aged and older adults, both of which have been shown to increase risk of cardiovascular disease.

26 Feb 2020

The Science Behind the Beer and Brewing Industry

Beer consists primarily of four ingredients; water, malted grain, hops, and yeast. Yet, the analysis of beer and the brewing process has changed dramatically over the last decade. In this interview, Christopher Welch from the Indiana Consortium for Analytical Science and Engineering (ICASE) talks to News-Medical Life Sciences about the new and improving developments in the analytical chemistry of beer and brewing analysis.

From Pittcon 23 Jan 2020

Anti-cancer effects of lycopene in tomatoes canceled out by iron-rich foods

Tomatoes have proven cancer-fighting properties, but new research suggests that eating them with iron-rich meats can destroy this effect.

18 Sep 2019

FDA expands approval of cystic fibrosis treatment to include pediatric patients as young as 6 years old

The U.S. Food and Drug Administration today expanded the indication for Symdeko (a combination of tezacaftor/ivacaftor) tablets for treatment of pediatric patients ages 6 years and older with cystic fibrosis who have certain genetic mutations.

22 Jun 2019

Study confirms QT-prolonging effects of grapefruit juice

Grapefruit juice is already listed as a substance to avoid when taking QT-prolonging medications because it increases the toxicity of many drugs.

9 May 2019

Coffee, sugary drinks, or alcohol? It's in your genes.

Researchers have discovered that choosing to consume alcohol, coffee, and sugar-sweetened drinks may be due to hertitable genetic variants.

6 May 2019

Using computer model to visualize brain's internal valuation system

Shopping in a supermarket can sometimes be an agony of choice. So many foods to choose from! And yet, we don't take hours to decide what we like to eat. Most of the time, we make decisions for or against certain products quickly and without much deliberation.

19 Feb 2019

Community hospitals link arms with prestigious facilities to raise their profiles

After seven years of a vigorous fight, Jim Hart worried he was running out of options. Diagnosed with prostate cancer at age 60, Hart had undergone virtually every treatment — surgery, radiation and hormones — to eradicate it. But a blood test showed that his level of prostate-specific antigen, which should have been undetectable, kept rising ominously. And doctors couldn’t determine where the residual cancer was lurking.

29 Jan 2019

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced detailed overall survival data from the PALOMA-3 trial, which evaluated IBRANCE (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy.

22 Oct 2018